Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2 (HEPVACHIV)

Aalborg University Hospital

Status and phase: Unknown; Phase 3

Conditions: Hepatitis A; Hepatitis B; HIV Infections

Treatments: Biological: interleukin-2; Biological: Twinrix

Study type: Interventional

Funder types: Other

Identifiers

NCT00451984

VN2005/32

Details and patient eligibility

About

The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults with stable antiretroviral therapy and negative for hepatitis A or B

Exclusion criteria

• Prior hepatitis A or B

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)